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Abstract: Mimicking nature is a powerful approach for developing novel lipid-based devices 
for drug and vaccine delivery. In this review, biomimetic assemblies based on natural or 
synthetic lipids by themselves or associated to silica, latex or drug particles will be discussed. In 
water, self-assembly of lipid molecules into supramolecular structures is fairly well understood. 
However, their self-assembly on a solid surface or at an interface remains poorly understood. In 
certain cases, hydrophobic drug granules can be dispersed in aqueous solution via lipid adsorption 
surrounding the drug particles as nanocapsules. In other instances, hydrophobic drug molecules 
attach as monomers to borders of lipid bilayer fragments providing drug formulations that are 
effective in vivo at low drug-to-lipid-molar ratio. Cationic biomimetic particles offer suitable 
interfacial environment for adsorption, presentation and targeting of biomolecules in vivo. 
Thereby antigens can effectively be presented by tailored biomimetic particles for development 
of vaccines over a range of defined and controllable particle sizes. Biomolecular recognition 
between receptor and ligand can be reconstituted by means of receptor immobilization into 
supported lipidic bilayers allowing isolation and characterization of signal transduction steps.
Keywords: cationic lipid, phospholipids, bilayer fragments, vesicles, silica, polymeric particles, 
antigens, novel cationic immunoadjuvants, drugs
Introduction
Particles are important in pharmaceutical and biomedical research since their size 
scale can be similar to that of proteins or DNA. They can mimic structural and func-
tional aspects of viruses, bacteria and other biological assemblies and are currently 
being used in: imaging;1 biosensing;2 gene and drug delivery;3 and vaccines.4,5 On the 
other hand, cationic lipids can be combined with negatively charged biomolecules or 
biological structures. Silica,6 latex,7 or hydrophobic drug particles8 have been coated 
with cationic lipids and characterized by means of adsorption isotherms, mean particle 
size from dynamic light scattering, surface potential analysis and colloidal stability. 
Properties of the intervening medium such as pH and ionic strength were system-
atically varied for achieving optimal lipid bilayer deposition and colloid stability.6,9 
Polystyrene sulfate (PSS) nanoparticles covered with a dioctadecyldimethylammonium 
bromide (DODAB) bilayer10 were used for adsorption of serum proteins,11 cholera 
toxin,11 Taenia crassiceps antigens,12,13 recombinant proteins,13,14 polysaccharides15–17 
and giant DNA.18 Similarly, lipid assemblies such as liposomes, vesicles, solid lipid 
nanoparticles and lipidic bilayer fragments (BF) or disks are as versatile as particles. 
Alec Bangham produced the first liposomes in 1965 in Cambridge UK.19 The liposome 
“membrane” model prepared from phospholipids has lead to much of our present International Journal of Nanomedicine 2010:5 250
Carmona-Ribeiro Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
knowledge on membrane properties. In addition, a variety 
of bilayer structures formed by dialkyldimethylammonium 
halides20 and other synthetic amphiphiles21–24 were introduced 
to mimic membrane properties furnishing unique opportuni-
ties to investigate structure-function relationships. Since the 
major requirement to form a supramolecular assembly of the 
bilayer type was an approximately cylindrical amphiphilic 
molecule with a geometric parameter between 0.5 and 1.0,25 
not only natural phospholipids were prone to form bilayers. 
Structural and functional aspects of biological membranes 
were also copied in a variety of biomimetic systems. Bilayers 
were the preferential supramolecular assembly for several 
synthetic amphiphiles as dialkyldimethylammonium bromide 
or chloride,20 sodium dihexadecylphosphate22,26,27 and many 
other molecules.28,29 However, lipid BF or disks remained as 
a much less explored bilayer assembly. Lately, our group has 
been developing novel formulations for hydrophobic drugs or 
vaccines based on these structures. Amphotericin B solubi-
lized at the rim of DODAB BF provided a novel formulation 
with excellent activity against systemic candidiasis in mice 
at low drug dose30,31 with low nephrotoxicity.32 BF have also 
been useful to cover particles such as silica, latex or insoluble 
drug particles with lipids.33,34 This mini-review aims at an 
overview on preparation, characterization and biomedical 
applications for lipid-based biomimetic particles.
Lipid BF or disks
Upon probe sonication of aqueous egg yolk lecithin disper-
sions, the high kinetic energy given by the sonicator to the 
lipid particles, caused their breaking down on colliding 
with each other.35 The collisions completely disrupted the 
multilamellar particles into short-lived bilayer fragments, 
which then reaggregated to form single-shelled vesicles of 
roughly uniform size.35 From this early study up to now, discs 
have been reported for a variety of amphiphiles and lipids in 
aqueous dispersions over a broad range of experimental con-
ditions.10,36 They were found from self-assembly of lipids and 
proteins,37–39 lipids and micelle-forming compounds40,41 lipids 
and hydrophilic polymers such as polyethylene-glycol lipids 
(PEGylated lipids)42,43 or charged lipids dispersed by probe 
sonication.27,44–46 The major repulsive interactions preventing 
fusion of lipid BF and discs in dispersion were electrostatic, 
steric and/or eletrosteric. In particular, probe sonication of the 
synthetic and cationic lipid dioctadecyldimethylammonium 
bromide (DODAB) can yield disrupted vesicles: the bilayer 
fragments, BF, or disks.10 The existence of BF in aqueous 
dispersions of sodium dihexadecylphosphate, or dioctadecy-
ldimethylammonium bromide or chloride obtained by probe 
sonication has been supported by the following evidences: 
(i) osmotic non-responsiveness of the dispersion indicative 
of absence of inner vesicle compartment;47 (ii) transmission 
electron microscopy (TEM) micrographs with electronic 
staining;27 (iii) cryo-TEM micrographs;45 (iv) fluid and solid 
state coexistence and complex formation with oppositely 
charged surfactant;48 (v) solubilization of hydrophobic drugs 
at the borders of DODAB bilayer fragments, which does not 
occur for DODAB closed bilayer vesicles.49,50 They differ 
from the closed vesicles by providing hydrophobic borders 
at their edges that are absent in closed bilayer systems such 
as vesicles or liposomes. Under conditions of low ionic 
strength, due to electrostatic repulsion, the charged BF 
remain colloidally stable in aqueous dispersions. These 
BF are not micelles; due to its cylindrical molecular shape 
DODAB or sodium dihexadecylphosphate (DHP) molecules 
self-assemble as bilayers.51,52 Figure 1 shows BF from 
different lipids.
The interaction between particles 
and bilayers for vaccines
The interaction between one bilayer vesicle and two micro-
spheres considering vesicles and particles of similar sizes 
can be electrostatic, electrodynamic (van der Waals) and/or 
hydrophobic.6,7,53–61 Figure 2 schematically illustrates possible 
interactions and assemblies.
In the first step (step 1), electrostatic and/or van der 
Waals and/or hydrophobic attraction leads to aggregation of 
a vesicle and a particle. These same interaction forces may 
disrupt the vesicle bilayer and promote bilayer adsorption 
onto the microsphere (step 2) and/or further aggregation 
with the other microsphere (step 2′). The adsorbed bilayer 
may attract the second microsphere (step 3). The hydrophobic 
interaction between an eventually hydrophobic surface and the 
hydrocarbon chains in the bilayer may completely destroy the 
bilayer structure flip-flopping the hydrocarbon chains onto 
the particle surface and generating a monolayered coverage 
on each microsphere (step 4). Lipid deposition from lipidic 
vesicles onto a solid surface would be determined initially 
by the classical combination of a repulsive force arising from 
the interaction of the electrical double layers associated with 
the vesicle and the surface and the attractive dispersion force 
between the vesicle and the solid. Vesicles are not, however, 
permanent rigid structures, and depending on their size, 
chemical composition, physical state of the bilayer and aque-
ous medium composition they can distort, aggregate, disrupt 
and fuse with each other. Deposition of vesicles onto a solid 
surface could give rise to any particular one or a combination International Journal of Nanomedicine 2010:5 251
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of these processes. Unilamellar phosphatidylcholine vesicles 
were reported to break open and adhere to a mica surface to 
form a bilayer coating.62
Phospholipid monolayers with lipid haptens inserted 
were supported by hydrophobic glass and useful for specific 
adherence of macrophages and cell surface recognition stud-
ies, but did not serve as hosts for transmembrane proteins.63 
Dipalmitoylphosphatidylcholine (DPPC) and phospha-
tidylinositol (PI) from vesicles adsorbed onto negatively 
charged ballotini (hydrophobic) glass beads as a monolayer 
with their head groups uppermost.64
The easiest method for preparing high quality phospho-
lipid bilayers on a flat hydrophilic surface was the direct 
fusion of small unilamellar vesicles.65 This method stemmed 
from making unilamellar membranes on glass coverslips for 
spectroscopic studies.65 Phospholipid fusion at the hydro-
philic surface such as freshly cleaved mica could be induced 
at elevated temperatures for those lipids of higher transition 
temperature with traces of divalent cations such as Ca2+. 
The other method for preparing supported membranes of 
biological interest was the controlled transfer of monolay-
ers to the surface using the Langmuir. trough. Using this 
method the content in each leaflet was easily controlled.66 
The main advantages of the vesicle fusion method seemed 
to be simplicity and the most natural lateral pressure in the 
bilayer in comparison to the lateral pressures obtained with 
the Langmuir trough. However, the content in each leaflet 
could not be controlled using fusion. Palmitoyloleoylphos-
phatidylcholine (POPC) vesicles without major protruding 
molecular moieties spread on a glass surface and formed 
A B
D C
Figure 1 A) Lipid BF of dioctadecyldimethylammonium bromide (DODAB)45 or B) sodium dihexadecylphosphate (DHP)27 or C) DSPC/cholesterol/PeG-DSPe(5000) mixtures 
at 12 mol% PeG-DSPe(5000)42 or D) DSPC: cholesterol: ceramide-PeG5000 carrying bacteriorhodopsin.43
Notes: with exception of micrograph in B) which was obtained by TeM after negatively staining the sample, all micrographs were obtained by cryo-TeM. In C), disks were 
observed edge-on (arrow) or face-on (arrow head). Bars denote 100 nm. Copyright  1995 and 1991 American Chemical Society;  2005 and 2007 elsevier.   Adapted with 
permission from Carmona-Ribeiro AM, Castuma Ce, Sesso A, Schreier S. Bilayer structure and stability in dihexadecyl phosphate dispersions. J Phys Chem. 1991;95:5361–5366. 
Johansson e, engvall C, Arfvidsson M, Lundahl P, edwards K. Development and initial evaluation of PeG-stabilized bilayer disks as novel model membranes. Biophys Chem. 
2005;113:183–192. Johansson e, Lundquist A, Zuo S, edwards K. Nanosized bilayer disks: attractive model membranes for drug partition studies. Biochim Biophys Acta. 
2007;1768:1518–1525. Andersson M, Hammarstrom L, Edwards K. Effect of bilayer phase transitions on vesicle structure, and its influence on the kinetics of viologen reduc-
tion. J Phys Chem. 1995;99(39):14531–14538.
Abbreviations: DHP, sodium dihexadecylphosphate; DODAB, dioctadecyldimethylammonium bromide; DSPe, distearoylphosphatidylethanolamine; PeG, polyethyleneglycol; 
TeM, transmission electron microscopy.
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Figure 2 The interaction between one bilayer vesicle and two particles. 6,7, 53–61 Copy-
right  1999 elsevier.   Adapted with permission from Carmona-Ribeiro AM, Lessa MM. 
Interactions between bilayer vesicles and latex. Colloids Surf A. 1999;153:355–361.International Journal of Nanomedicine 2010:5 252
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a supported planar bilayer.67 In contrast, Escherichia coli 
(E. coli) lipid vesicles adsorbed as entire vesicles to the 
surface forming a supported vesicle layer on glass.67 The 
difference in behavior upon deposition on glass was due to 
chemical structure of E. coli lipids. Lipopolysaccharides 
from E. coli are bulky and have strongly hydrated polar 
heads. Their vesicles simply adhered and formed a supported 
vesicle layer on glass.67 Fusion in-between vesicles attached 
to the surface was prevented by steric repulsion.67 For DPPC 
and DSPC bilayers on hydrophilic silicon/water interface, 
single and double bilayers have been prepared and character-
ized via neutron reflectivity.68 This technique investigated the 
structure, hydration and roughness of the layers and allowed 
to determine the distance between two deposited bilayers.68 
The outermost bilayer was highly hydrated and floated at 2 to 
3 nm above the first one.68 Adhesion of a DODAB vesicle 
layer onto the rough and highly hydrated surface of cells 
was electrostatically driven. Cationic vesicles at low ionic 
strength surrounded the bacterial cell as a vesicle layer.69 
Absence of DODAB vesicle disruption upon interaction 
with the bacteria was depicted from absence of [14C]-sucrose 
leakage from large vesicles in experiments where this 
marker was used to label the inner water compartment of the 
vesicles.70 Given the quaternary ammonium moiety of the 
DODAB molecule, its antimicrobial effect was systemati-
cally evaluated and its differential cytotoxicity established 
as illustrated in Table 1.
In spite of its dose dependent-toxicity, DODAB induced 
delayed-type hypersensibility (DTH), a marker for cell-
mediated immune responses. This interesting property 
allowed DODAB to find many uses as an efficient immunoad-
juvant mainly for veterinary uses but also in humans in a few 
instances.13,74–79 Supramolecular assemblies of DODAB BF 
by themselves or after interaction with supporting particles 
were recently combined with three different model antigens 
in separate and tested as immunoadjuvants.13 DODAB-based 
immunoadjuvants carrying antigens at reduced DODAB 
dose (0.01–0.1 mM) induced superior DTH responses in 
mice in comparison to alum. Thus, the cationic immunoad-
juvant was either reduced to a single-component, nanosized 
system – DODAB BF – or was a dispersion of cationic 
particles with controllable nature and size as obtained after 
covering silica or polystyrene sulfate latex (PSS) with a 
cationic DODAB bilayer. DODAB BF interacted with pro-
teins both via the hydrophobic effect and the electrostatic 
attraction at low ionic strength. DODAB based adjuvants 
exhibited good colloid stability while complexed with the 
antigens, complete absence of toxicity in mice (ie, local or 
general reactions) and a remarkable induction of Th1 immune 
response at reduced doses of cationic and toxic DODAB lipid. 
DODAB vesicle disruption by probe sonication at low ionic 
strength (0.1–5.0 mM monovalent salt) produced DODAB 
BF which remained electrostatically stabilized in dispersion 
by the electrostatic repulsion in between fragments. DODAB 
BF also interacted with oppositely charged particles such 
as silica or polystyrene sulfate (PSS) latex to produce the 
cationic particulates. Figure 3 schematically introduced the 
novel cationic immunoadjuvants based on reduced DODAB 
doses and their compared DTH response.12–14
The final DODAB concentration required to cover all 
particles with a bilayer can be easily calculated from total 
surface area for particles and bilayers and from the mean 
molecular area for the lipid at the air-water interface.6,7,11,56 
Sizing, zeta-potentials and polydispersity index for the novel 
cationic adjuvants as compared to the similarly cationic 
Al(OH)3 evidenced a superior colloid stability in contrast to 
the one exhibited by alum.13,14 Table 2 illustrates the physical 
properties of DODAB BF, PSS/DODAB and silica/DODAB 
used in Figure 3 for antigen presentation.
Chemical, biological (eg, engineered viruses and bacteria), 
polymeric or liposomal adjuvants have been developed and 
tested for vaccines.4,5,80–83 However, most of them induced 
Table 1 Differential cytotoxicity of DODAB against some eukaryotic* and prokaryotic cells**
Cell type Viable cells/mL [DODAB]50%survival/mM Ref.
Normal Balb-c 3T3 mouse fibroblasts* 104 1.000 71
SV40-transformed SVT2 mouse fibroblasts* 104 1.000 71
C. albicans* 2 × 106 0.010 72
E. coli** 2 × 107 0.028 70, 73
S. typhimurium** 2 × 107 0.010 73
P. aeruginosa** 3 × 107 0.005 73
S. aureus** 3 × 107 0.006 73
Abbreviation: DODAB, dioctadecyldimethylammonium bromide.International Journal of Nanomedicine 2010:5 253
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local reactions.86,87 and production of immunoglobulin E (IgE) 
both associated with some allergic reactions in humans.88,89 In 
addition to Alum, MF59,90–95 virosomes96–98 and L-tyrosine99 
represented new and safe adjuvants and carrier systems 
recently licensed in some countries for human use.
Particles are taken up by antigen presenting cells (APC) 
more effectively than soluble antigen.100,101 Optimal APC 
uptake of positively charged particles with diameters of 
500 nm and below was reported.102 Furthermore, particles with 
a positive charge showed higher internalization into human 
breast cancer cells than those with negative charge, while 
the degree of internalization of the positively and negatively 
charged nanoparticles into human umbilical vein endothelial 
cells was almost the same.103 Particles coated by cationic lipid 
were optimized regarding bilayer deposition.6,9,12,18 This was 
possible from systematic studies of effects of ionic strength 
and concentrations for particles and cationic lipid. Due to 
the microbicidal effect of cationic lipids and surfactants,104 
cationic particles turned out to be extremely toxic to bacteria, 
a major problem while trying to transform these microor-
ganisms by means of cationic particle/DNA assemblies.18 
The bacteria cannot be genetically modified if they die. 
Silica,6,56,57,61 latex7,105 or hydrophobic drug particles4,33,49 have 
been coated with cationic lipids. Although DODAC or DHP 
electrostatically adsorbed to oppositely charged polystyrene 
microspheres, forming homodisperse bilayer-covered lattices, 
this took place only over a certain range of low lipid concen-
trations.7,12,53,54 Beyond bilayer deposition, there was vesicle 
adhesion to the bilayer-covered latex.53 Using radiolabeled 
D-glucose inside the cationic vesicles at very low ionic 
strength, cationic liposome adsorption was accompanied of 
vesicle disruption evidencing formation of a bilayer on the 
solid particle surface.53 A series of monodisperse PSS disper-
sions (76–412 nm mean diameter) were coated with DODAB 
bilayers so that the biomimetic particles are available over 
a range of controllable sizes.18,54 The zeta-potential of these 
bilayer-covered particles in water remained constant (and 
positive) over the entire range of sizes tested.
Whereas polystyrene microspheres have a hydrophobic 
surface, silica particles are good models for hydrophilic 
surfaces. Silica interacts with erythrocytes, lysosomes, 
macrophage plasma membranes and liposomes106 but the 
mechanism of the interaction between silica and phospho-
lipid membranes is still controversial. The main possibilities 
are: 1) silica particles binding dipalmitoylphosphatidyl-
choline (DPPC) through hydrogen bonds between Si-OH 
and O = P- groups; 2) tetraalkylammonium groups at the 
extracellular region of the erythrocyte membrane forming 
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Figure 3 Superior performance of novel DODAB-based adjuvants inducing DTH in 
mice as compared to alum. The same antigen (Ag) carried by each adjuvant was used for 
immunization.   Ag was carried by DODAB BF at 0.1 mM DODAB (DODAB BF/Ag) or by 
PSS/DODAB or silica/DODAB particles at 0.01 or 0.05 mM DODAB (PSS/DODAB/Ag or 
silica/DODAB/Ag), respectively, or by alum (Al(OH)3/Ag).   After immunization, elicitation 
of the swelling response was done by injecting Ag alone in the footpad so that % footpad 
swelling was measured in comparison to alum. Copyright  2007, 2009 elsevier.   Adapted 
with permission from Lincopan N, espíndola NM, vaz AJ, Carmona-Ribeiro AM. Cationic 
supported lipid bilayers for antigen presentation. In. J Pharm. 2007;340:216–222. Lincopan 
N, espíndola NM,  vaz AJ, et al. Novel immunoadjuvants based on cationic lipid: preparation, 
characterization and activity in vivo.   Vaccine. 2009;27:5760–5771. Lincopan N, Santana MRA, 
Faquim-Mauro e, da Costa MHB, Carmona-Ribeiro AM. Silica-based cationic bilayers as 
immunoadjuvants. BMC Biotechnol. 2009;9:article 5.
Abbreviations:  DODAB, dioctadecyldimethylammonium bromide; PSS, polystyrene 
sulfate; DTH, delayed-type hypersensibility; BF, bilayer fragments.
side effects and/or showed a lack of universality for dif-
ferent antigens or routes of administration. At present the 
only adjuvant licensed worldwide for humans is repre-
sented by aluminum salts, mainly aluminum hydroxide and 
aluminum phosphate.84,85 They elicit high and long lasting 
antibody titers and Th2 type responses but are poor inducers 
of cytotoxic T lymphocytes (CTLs), the most important cellu-
lar defense against infectious diseases caused by intracellular 
pathogens (eg, HIV and Mycobacterium tuberculosis) and 
tumors.84 Furthermore, alum adjuvants can induce occasional International Journal of Nanomedicine 2010:5 254
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ion pairs with dissociated silanol on the silica particle and 
generating hemolytic effects observed for silica. Adsorption 
isotherms of 4 different bilayers on hydrophilic silica over a 
range of experimental conditions helped to clarify this issue.56 
The separate use of synthetic charged membranes with phos-
phate or tetraalkylammonium groups as polar heads such as 
are DODAB and DHP bilayer vesicles, to obtain adsorption 
isotherms on silica established the relative importance of 
phosphate or tetraalkylammonium on the mechanism of 
phospholipid deposition onto hydrophilic silica particles. 
Formation of ion pairs between the quaternary ammonium in 
the choline moiety of the phospholipid and the deprotonated 
silanol drove vesicle adhesion to the particle but vesicle rup-
ture and bilayer deposition was determined by the cooperative 
occurrence of several hydrogen bridges between silanol and 
the phosphate moiety on the phospholipid.56 There was a low 
affinity between neutral phospholipids and the silica surface 
and a high affinity for the cationic amphiphile over a range 
of pH values.57 Tris-hydroxymethylaminomethane (Tris) 
used as a buffer increased the affinity between PC and silica 
at pH  7.4 due to Tris adsorption on silica with an increase 
in the surface density of hydroxyls on the surface available 
to hydrogen bridging with phosphate phospholipid groups. 
Bilayer deposition, however, was unambiguously confirmed 
by the three techniques only for the interaction DPPC 
vesicles/silica over 1 hours at 65°C and for the interaction 
DODAB vesicles/silica over the all range of experimental 
conditions tested.57 A simple spectrophotometric method for 
identifying entire bilayer deposition onto solid particles was 
developed from incorporation of the optical probe merocya-
nine 540 onto the outer bilayer vesicle surface. Upon bilayer 
deposition on the particle, sandwiching the marker between 
bilayer and solid particle reduced light absorption. Thereby 
reduction of light absorption by merocyanine was quanti-
tatively related to bilayer deposition.57 For the interaction 
between cationic DODAB/DPPC and anionic PI/DPPC ves-
icles with zinc citrate dispersions the majority of the adsorp-
tion was in the form of intact liposomes.107 When liposomes 
interacted with hydrophilic solid surfaces bearing ionizable 
groups such as citrate or silanol, the pH affected the extent 
of adsorption.107 For anionic liposomes, adsorption decreased 
with pH. For cationic liposomes, adsorption increased with 
pH.107 The fusion and spreading of phospholipid bilayers on 
negatively charged glass surfaces was dependent on pH and 
ionic strength.108 Membrane fusion of negatively charged 
membranes was favored by low pH and high ionic strength 
whereas membrane fusion of positively charged membranes 
onto the surface occurred under all conditions tested.108
The interaction between particles 
and bilayers for drug delivery
The particle concept encompasses a broad variety of par-
ticulates: lipid particles (eg, a bilayer fragment); polymeric; 
mineral or metallic particles; bacterial cells; viruses; mam-
malian cells with several organelles and particles of insoluble, 
hydrophobic drugs. The lipid covered-latexes were useful 
as hosts for receptors,60,109,110 as coatings reducing protein 
adsorption on the particles110 and in chromatography.111–113 The 
potential of hybrid particle-lipid systems in diagnostics and 
therapeutics has also been realized.8,114–116 In drug formulation, 
lipid nanoparticles of the anticancer drug chlorambucil were 
prepared by ultrasonication, using stearic acid as the core lipid 
and DODAB as surface modifier.117 The presence of DODAB 
on the lipid nanoparticles resulted in greater accumulation 
of the drug in tumors.117 For the encapsulation of cisplatin, 
bilayer-coating circumvented the limited solubility of cisplatin 
Table 2 Physical properties of the novel cationic immunoadjuvants in a1 mM NaCl (pH 6.3) or b5 mM TrisHCl (pH 7.4) at 5 × 109 PSS 
particles/ml or 0.1 mg/ml silica or 0.1 mg/ml Al(OH)3. Copyright  2009 elsevier.   Adapted with permission from Lincopan N, espíndola NM,  vaz 
AJ, et al. Novel immunoadjuvants based on cationic lipid: preparation, characterization and activity in vivo. Vaccine. 2009;27:5760–5771.
Dispersion DODAB/mM Mean diameter/nm Zeta-potential/mV Polydispersity index
DODAB BFa 1.0 73 ± 1 42 ± 2 0.240 ± 0.01
PSSa – 236 ± 4 -61 ± 1 0.130 ± 0.03
PSS/DODABa 0.01 246 ± 3 44 ± 3 0.085 ± 0.03
Al(OH)3
a – 458 ± 3 28 ± 3 0.191 ± 0.04
DODAB BFb 1.0 74 ± 1 33 ± 5 0.270 ± 0.04
Silicab – 294 ± 2 -47 ± 2 0.180 ± 0.02
Silica/DODABb 0.05 373 ± 7 33 ± 2 0.260 ± 0.02
Al(OH)3
b – 700 ± 20 14 ± 2 0.317 ± 0.01
Abbreviations: DODAB, dioctadecyldimethylammonium bromide; PSS, polystyrene sulfate; DTH, delayed-type hypersensibility; BF, bilayer fragments.International Journal of Nanomedicine 2010:5 255
Biomedical applications of biomimetic nanoparticles Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
in water and produced cisplatin nanocapsules, bean-shaped 
nanoprecipitates of cisplatin coated by a lipid bilayer.118 The 
nanocapsules represented a novel lipid formulation of cisplatin 
characterized by a very high cisplatin-to-lipid ratio and cyto-
toxicity against tumor cells in vitro as compared to the free 
drug. The formation of the nanocapsules critically depended 
on the presence of negatively charged phospholipids and posi-
tively charged aqua-species of cisplatin.118,119 The effect of PEG 
on the stability of the cisplatin nanocapsules was studied by 
incorporating PEG conjugated to phosphatidylethanolamine 
(DSPE-PEG2000).120 Cisplatin release from the nanocapsules 
depended on the temperature, the surrounding medium, and 
the lipid composition of the bilayer coat. Sterically stabilized 
cisplatin nanocapsules containing 6 mol % DSPE-PEG served 
as the starting formulation for in vivo studies addressing the 
anti-tumor efficacy of cisplatin nanocapsules in tumor-bearing 
mice; there was a requirement of anionic phospholipid for suc-
cessful nanoencapsulation of the cationic aqua-cisplatin.120
Miconazole or amphotericin B were formulated in 
DODAB or DHP BF.34,49 Some of these formulations required 
low drug-to-lipid molar ratio due to limited drug loading 
capacity of the BF at their rims. For example, BF loading 
capacity for monomeric amphotericin B was 0.1 mM ampho-
tericin B at 2 mM DODAB meaning that one drug molecule 
required 20 molecules of cationic lipid to become soluble in 
the BF nanostructure. At and above this 1:20 drug-to-lipid 
molar ratio, all solubilization sites at the rim of the BF were 
occupied. Therefore, further addition of drug resulted in 
appearance of aggregated amphotericin B in the dispersion 
as easily monitored by systematic determination of size dis-
tribution by means of photon correlation spectroscopy.
In order to formulate hydrophobic drugs with the 
DODAB lipid at high drug-to-lipid molar ratios, we took 
advantage of the “sticky” property of chaotropic dihydrogen 
phosphate anion which converted miconazole or ampho-
tericin B drug particles into negatively charged particles. 
Thereafter, anionic drug particles could be coated by the 
DODAB cationic lipid.34,49 These formulations were tested 
against C. neoformans and Candida and were very effective 
due to DODAB activity against fungi. The cationic lipid alone 
exhibited minimal fungicidal concentrations (MFC) equal to 
2 and 2 to 250 mg/L against C. neoformans and Candida, 
respectively. In combination, over the first hour, fungicidal 
activity was due to DODAB with lipid capsules retarding 
drug action. At 48 hours and 104 cfu/mL, MFC (mg/L) against 
Candida albicans was reduced from 4 to 1 amphotericin B 
(at 2 DODAB), and from 8 to 1 miconazole (at 1 DODAB). 
Calculations of synergism indexes showed synergistic action 
of both antimicrobial drugs: the cationic DODAB lipid and 
the microbicidal drug34,49 so that the DODAB/miconazole 
(MCZ) formulations should be further tested regarding thera-
peutic activity in vivo. Table 3 illustrated the efficacy of MCZ 
in DODAB or DHP BF despite the low dose of drug.
In summary, two major strategies were developed to formu-
late hydrophobic drugs with bilayer fragments. These strategies 
can be better visualized in Figure 4. In Figure 4 (a), coalescence 
of BF around the drug granule would encapsulate drug par-
ticles at high drug-to-lipid molar ratios.33,34,49,50 In Figure 4 (b), 
monomolecular drug solubilization would be achieved at low 
drug-to-lipid molar ratios.30,31,33 Therefore, these discoidal, 
charged BF dispersed the hydrophobic drug particles in water 
both at low and high drug-to-lipid molar ratios.
PEG decorated lipid bilayers are widely used in drug 
delivery.121 In these hybrid polymer/lipid systems, there is a 
transition from a dispersed lamellar phase (liposomes) to a 
micellar phase mediated by the formation of small discoidal 
micelles. The onset of disk formation took place at low 
PEG-lipid concentrations (5 mol%) and the size of the 
disks decreased as more PEG-lipid was added to the lipid 
mixture.122 Stable dispersions dominated by flat bilayer disks 
could be prepared from a carefully optimized mixture of 
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), choles-
terol, and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-
N-[methoxy(polyethyleneglycol)-5000][PEG-DSPE(5000)]. 
By varying the content of PEG-DSPE (5000), the disks 
diameter varied from about 15 to 60 nm. Disks compared 
favorably to uni- and multilamellar liposomes for hydrophilic 
drug partitioning employing immobilized disks in glass 
capillaries.42 The major repulsive interactions preventing 
fusion of these BF were steric. They provided larger areas 
Table 3 Minimal fungicidal concentration (MFC) for Zoltec® 
(fluconazol), miconazole (MCZ), MCZ/DODAB BF or MCZ/DHP 
BF against Candida albicans. Copyright  2006 elsevier. Adapted 
with permission from  vieira DB, Pacheco LF, Carmona-Ribeiro AM. 
Assembly of a model hydrophobic drug into cationic bilayer frag-
ments. J Colloid Interface Sci. 2006;293:240–247.
Dispersion MFC
µM mg/mL
Zoltec® 6.5 2
DODAB 4000 250
MCZ 8 4
MCZ and DODAB 2 1
MCZ and DHP 4 2
Abbreviations: DODAB, dioctadecyldimethylammonium bromide; PSS, polystyrene 
sulfate; DTH, delayed-type hypersensibility; BF, bilayer fragments.International Journal of Nanomedicine 2010:5 256
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than vesicles or liposomes for hydrophilic drug partitioning 
and from this point of view were considered as an attractive 
and sometimes superior alternative to liposomes.43
Reconstitution of receptor-ligand recognition in artificial 
biomimetic particles is a very promising but hitherto unex-
plored area for research. The major advantage of these par-
ticles is the possibility of complete quantification of binding 
from simple analytical methods and techniques such as cen-
trifugation for separation between free and bound receptors or 
free and bound ligands. Aiming at the production of bilayer 
covered silica particles, the interaction between silica par-
ticles and lipid vesicles or BF has been systematically studied 
by our group since 1997.56–61 As a result optimal coverage of 
silica particles with a PC bilayer was recently achieved.59,60 
At pH 6.3, limiting PC adsorption indicative of one-bilayer 
deposition on each silica particle was obtained at and above 
10 mM NaCl. Increasing ionic strength provided increasing 
attractive van der Waals attraction between vesicle and 
particle so that vesicles ruptured upon contact with particles 
and covered them with one bilayer.59 Keeping ionic strength 
at 10 mM NaCl, the effect of increasing pH was decreasing 
affinity between PC and silica.59 These experiments revealed 
an important role for hydrogen bonding between silanol on 
silica and phosphate on PC driving bilayer deposition. Bilayer 
deposition improved colloid stability of silica as shown from 
absence of particulate sedimentation.59
Silica-based biomimetic particles successfully immobi-
lized proteins or DNA13 or allowed isolation and reconstitu-
tion of receptor-ligand specific interaction.60
Cholera toxin (CT) and its receptor, the monosialogan-
glioside GM1, a cell membrane glycolipid, self-assembled 
on PC bilayer-covered silica at 1 CT/5 GM1, a molar ratio 
in perfect agreement with literature. Figure 5 illustrated this 
proof of concept.
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Figure 5 Receptor-ligand recognition on biomimetic particles.60 Cryo-TeM revealed the PC bilayer surrounding a silica particle. The GM1 receptor inserted in supported PC 
bilayers recognized its ligand, the cholera toxin. Copyright  2005 American Chemical Society. Adapted with permission from Mornet S, Lambert O, Duguet e, Brisson A. The 
formation of supported lipid bilayers on silica nanoparticles revealed by cryoelectron microscopy. Nano Lett. 2005;5:281–285
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Figure 4 A) encapsulation of amphotericin B particle by a cationic bilayer at high drug to lipid molar ratio; B) Solubilization of amphotericin B at the rim of cationic BF at 
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Conclusions
The intermolecular forces between lipids and particles have 
to be understood in depth before optimal biomimetic particles 
based on lipids can be obtained. Over the years our system-
atic studies on such interactions produced some examples 
of optimized bilayer deposition on silica or latex particles. 
Furthermore, charged BF solubilized hydrophobic drugs 
and complexed with antigens yielding novel supramolecular 
assemblies for drug and vaccine delivery either by providing 
hydrophobic edges for drug or antigen complexation 
or by covering silica, drug or polymeric particles with 
minute amounts of lipid. Low doses of cationic lipid in 
the formulations avoided their well described toxicity. Our 
contribution to the field may be summarized in a thorough 
description of the differential cytotoxicity of the DODAB 
cationic lipid, and the invention of novel charged carriers to 
formulate drugs or vaccines at reduced charged lipid dose. 
Encapsulation of drugs, reconstitution of biomolecular 
recognition, antigen presentation and antimicrobial therapy 
were some examples of biomedical applications for biomi-
metic particles that were provided by this mini-review.
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